Discover. Oncology最新文献

{"title":"T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects.","authors":"Guangmin Wan, Lu Yang, Quan Wang, Gang Xu","doi":"10.1007/s12672-025-02239-2","DOIUrl":"10.1007/s12672-025-02239-2","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER-2) serves as a pivotal target for breast cancer treatment and a vital prognostic marker. Anti-HER-2 therapies, which are integral to the management of HER-2-positive breast cancer, including monoclonal antibodies (e.g., trastuzumab and pertuzumab), tyrosine kinase inhibitors (e.g., lapatinib and pyrotinib), and antibody-drug conjugates (ADCs) such as trastuzumab emtansine (T-DM1). ADCs consist of a monoclonal antibody, a linker, and a cytotoxic payload, engineered to deliver chemotherapy selectively to tumor cells, thereby reducing the systemic toxicity associated with traditional chemotherapy. T-DM1, a HER-2-targeting ADC, combines the humanized anti-HER-2 IgG1 trastuzumab with DM1, a cytotoxic agent that inhibits microtubule formation. T-DM1 has significantly enhanced the prognosis of HER-2-positive breast cancer patients who fail to achieve a pathological complete response or develop distant metastases after neoadjuvant trastuzumab and pertuzumab therapy. While the combination therapy of T-DM1 with radiotherapy demonstrates an acceptable safety profile overall, clinicians should remain vigilant regarding potential severe treatment-related toxicities that have been observed in specific clinical scenarios. Nevertheless, limited research exists regarding the adverse effects and mechanisms of T-DM1 in combination with radiotherapy. This review investigates preclinical studies on the interactions between T-DM1 and radiotherapy, investigates associated adverse effects and their underlying mechanisms, identifies predictive factors and prognostic implications, and explores potential therapeutic strategies involving the concurrent T-DM1 with radiotherapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"857"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies and prognostic insights for lacrimal gland adenoid cystic carcinoma: a review.","authors":"Xinyun Wang, Huiling Ma, Ying Chen, Menghui Zhang, Sisi Liu, Huiyan Li, Xiawei Wang, Hongguang Cui","doi":"10.1007/s12672-025-02468-5","DOIUrl":"10.1007/s12672-025-02468-5","url":null,"abstract":"<p><p>Adenoid cystic carcinoma (ACC) is the most common type of malignant tumor in lacrimal gland cancer. The primary treatment approach involves eye-preserving surgery combined with adjuvant radiotherapy, which has proven effective in maintaining visual function and achieving favorable local control with minimal toxicity. However, the 5-year survival rate for ACC of the lacrimal gland remains below 60%. Recently, novel adjuvant therapies, including neoadjuvant intra-arterial chemotherapy, proton radiotherapy, and neutron radiotherapy, have significantly improved survival outcomes. Despite these advances, the rarity of lacrimal gland adenoid cystic carcinoma (LGACC) limits comprehensive studies on long-term survival and the potential for late toxicity, underscoring the need for further research. Additionally, recent findings on pathogenic mechanisms and proteomic abnormalities in LGACC offer a foundation for developing targeted therapies, paving the way for more personalized treatments. This article reviews contemporary treatment strategies and prognostic insights for LGACC, focusing on recent advancements and their implications for patient survival.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"858"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of metabolic reprogramming-related key genes in hepatocellular carcinoma after transcatheter arterial chemoembolization treatment.","authors":"Tongfei Li, Shujuan Liu, Shengjun Wang, Shan Sun, Feng Ji, Mingliang Li, Yong Zhang","doi":"10.1007/s12672-025-02606-z","DOIUrl":"10.1007/s12672-025-02606-z","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming plays an important role in therapeutic efficacy of hepatocellular carcinoma (HCC). However, the metabolic reprogramming-related key genes associated with transcatheter arterial chemoembolization (TACE) treatment sensitivity in HCC remain further investigation.</p><p><strong>Methods: </strong>We analyzed data from public databases, The Cancer Genome Atlas and Gene Expression Omnibus, as well as metabolism-related genes (MRGs), to identify key genes associated with TACE treatment sensitivity. Further analysis was conducted on the relationship between key genes and immune cell infiltration, HCC-related genes, regulatory network construction, nomogram construction, and drug sensitivity analysis. Finally, the expression of key genes was validated based on databases and in vitro RT-qPCR.</p><p><strong>Results: </strong>Four key genes (CDC20, LPCAT1, PON1, and SPP1) associated with TACE treatment sensitivity were identified. Increased CDC20, LPCAT1, and SPP1 and reduced PON1 were found in tumor tissues than normal tissues, as well as in advanced patients than early-stage patients. Lower expression of CDC20, LPCAT1, and SPP1, and higher expression of PON1 were detected in responsive patients than non-responsive patients. Patients with high expression of CDC20, LPCAT1, and SPP1, and low expression of PON1 had poor prognosis. They were also correlated with tumor immune microenvironment and sensitivity to multiple chemotherapy drugs. The expressions of key genes at the gene and protein levels were validated.</p><p><strong>Conclusions: </strong>Our study provided systematic insights into identification of biomarkers for TACE treatment sensitivity in HCC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"861"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a m6 A-associated lncRNAs-derived risk model for enhanced patient prognosis stratification and personalized therapy approaches in bladder cancer.","authors":"Renhu Chen, Yuqing Ye, Yuxuan Zheng","doi":"10.1007/s12672-025-02646-5","DOIUrl":"10.1007/s12672-025-02646-5","url":null,"abstract":"<p><strong>Introduction: </strong>Bladder cancer (BCa) is a leading malignancy in the urinary tract system, often resulting in poor prognosis due to rapid relapse and metastasis, with a low 5-year survival rate. Although the role of N6-methyladenosine (m6A) methylation and long noncoding RNAs (lncRNAs) is implicated in BCa progression, research on how lncRNAs influence BCa prognosis and potential therapeutic interventions remains scarce.</p><p><strong>Methods: </strong>RNA expression profiles and gene mutations for 406 BCa patients were retrieved from the The Cancer Genome Atlas (TCGA) database. A comprehensive dataset was established to correlate lncRNAs with 21 identified m6A-associated genes, categorized into writers, erasers, and readers. Pearson correlation analysis between these m6A genes and lncRNAs was performed and a prognostic model derived from m6A-associated lncRNAs was developed. Immune infiltration was analyzed using multiple evaluative methods and the correlation between single nucleotide variant (SNV) mutations and drug sensitivity was assessed for the correlative relationship with the m6A-associated lncRNA-derived risk scores.</p><p><strong>Results: </strong>We identified 3,462 m6A-associated lncRNAslinked to BCa prognosis, of which 238 lncRNAs showed significant associations with overall survival in BCa patients. A m6A-associated lncRNA-derived risk model comprising 26 selected lncRNAs was developed using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression, where BCa patients with higher m6A-associated lncRNA-derived risk scores had poorer outcomes. The prognostic significance and reliability was validated, with an area under the curve (AUC) value exceeding 0.7 at multiple time points. Additionally, a nomogram integrating clinical features and m6A-associated lncRNA-derived risk scores had enhanced prognostic accuracy over other clinical indicators, with promise for clinical decision-making. A negative correlation was observed between m6A-associated lncRNA-derived risk scores and tumor mutational burden (TMB). Moreover, patients with high m6A-associated lncRNA-derived risk score group showed significant enrichment of regulatory T cells (Tregs), M2 macrophages, and fibroblasts, highlighting the potential involvement of immune and stromal cells in these BCa patients.</p><p><strong>Conclusion: </strong>These findings highlight the prognostic value and clinical relevance of m6A-associated lncRNAs in BCa for future patient stratification and personalized therapy approaches.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"856"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis Neddylation-related genes identified UBB as a prognostic biomarker for clear cell renal cell carcinoma.","authors":"Shengren Cen, Yingpeng Li, Xinhao Xiong, Zihong Ma, Yongsheng Wang, Xingcheng Gao","doi":"10.1007/s12672-025-02547-7","DOIUrl":"10.1007/s12672-025-02547-7","url":null,"abstract":"<p><p>Neddylation, as a type of post-translational modification, plays a key role in cancer development. However, the biological characteristics and clinical prognosis value of Neddylation-related genes (NRGs) signatures in clear cell renal cell carcinoma (ccRCC) remain undetermined. Here, we identified two subtypes of NRGs in ccRCC based on TCGA data and constructed a NRGs risk signature (NRGS). Survival analysis, ROC curves, and nomograms showed that NRGS was an important predictor of prognosis in patients with clear cell renal cell carcinoma. We further revealed important correlations between NRGS and clinicopathological features, gene mutations, drug sensitivity, and immune cell infiltration. High NRGS indicates a poorer prognosis for kidney cancer, but higher remission rates with immunotherapy. Drug sensitivity also varies across risk groups. UBB was identified as a hub gene for NRGS and was downregulated in ccRCC, which is associated with poor prognosis. In conclusion, this study provides strategies for predicting prognosis and individualizing treatment for ccRCC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"859"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer.","authors":"Zehua Shu, Xinyi Liu, Xiaoyan Li, Siming Fu, Sheng Li, Gaolei Liu, Zhouting Tuo, Weihua Lan, Baohua Lan, Yao Zhang","doi":"10.1007/s12672-025-02634-9","DOIUrl":"10.1007/s12672-025-02634-9","url":null,"abstract":"<p><strong>Background: </strong>The role of RAP1GAP in tumor progression has garnered increasing attention; however, its prognostic value and immunological influence across various cancers remain uncertain. Our study presents a pan-cancer analysis to investigate its involvement in oncogenesis and immune regulation.</p><p><strong>Methods: </strong>Public databases were utilized to assess RAP1GAP expression across cancers. Cox regression analysis evaluated its prognostic value, while Pearson correlation examined associations with genomic heterogeneity, tumor stemness, immune cell infiltration, and immune checkpoints. Immunohistochemical staining of bladder cancer and adjacent tissues assessed RAP1GAP expression and clinical correlations.</p><p><strong>Results: </strong>RAP1GAP expression is differentially expressed in a variety of tumor types and predicts a better or worse prognosis for tumor patients. It was strongly linked to genomic heterogeneity and tumor stemness in multiple cancers. Immunohistochemistry showed increased RAP1GAP expression in bladder cancer. Immune cell analysis revealed high RAP1GAP expression was associated with greater infiltration of plasma cells, naive CD4 ⁺ T cells, Tregs, and eosinophils, while low expression correlated with increased CD8 ⁺ T cells, activated memory CD4 ⁺T cells, and M1 macrophages.</p><p><strong>Conclusion: </strong>RAP1GAP is a potential prognostic biomarker and immune regulator, with promising implications as an immunotherapeutic target for bladder cancer.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"863"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between red cell distribution width and lung cancer: evidence from Mendelian randomization and National Health and Nutrition Examination Survey.","authors":"Yongli Liu, Jiajia Qu, Chenyang Hu, Wei Zhao, Yuxin Zhang, Yuchen Luo, Yiqing Qu","doi":"10.1007/s12672-025-02718-6","DOIUrl":"10.1007/s12672-025-02718-6","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains a primary contributor to cancer-related mortality globally. Red blood cell distribution width (RDW), a straightforward and cost-effective indicator, measures the variability in red blood cell size and is conventionally employed in hematological assessments for anemia differentiation. Nonetheless, limited research has explored the causal link between RDW levels and lung cancer incidence.</p><p><strong>Methods: </strong>Initially, Mendelian randomization (MR) was employed to explore the underlying causal connection between RDW and lung cancer. To ensure the robustness of the MR findings, sensitivity analyses were conducted. Following this, the National Health and Nutrition Examination Survey (NHANES) database was utilized to further substantiate the influence of RDW on the prognosis of lung cancer.</p><p><strong>Results: </strong>The MR analysis revealed a significant association between RDW and lung cancer risk in the European population (OR IVW 1.11, 95% CI 1.03-1.20, p = 0.006; OR Weighted-median 1.16, 95% CI 1.03-1.31, p = 0.013; OR MR-Egger 1.14, 95% CI 1.00-1.30, p = 0.059). Furthermore, findings from the NHANES database suggested that lower RDW values are associated with improved prognosis in lung cancer patients (HR 2, 95% CI 1.07-3.74, p < 0.05).</p><p><strong>Conclusions: </strong>Our study provides further evidence for the relationship between RDW levels and lung cancer, highlighting the potential significance of RDW as a biomarker for predicting lung cancer risk and prognosis.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"867"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of N6-methyladenosine methyltransferase component RBM15 in cancer progression and its therapeutic potential.","authors":"Wenxiang Shen, Yulong Ma, Chunwang Yang, Shishun Yan, Kaishan Ye","doi":"10.1007/s12672-025-02644-7","DOIUrl":"10.1007/s12672-025-02644-7","url":null,"abstract":"<p><p>Cancer ranks as a primary cause of mortality globally, and the study of its molecular markers and regulatory mechanisms holds paramount importance. N6-methyladenosine (m⁶A) represents the predominant modification in messenger RNA (mRNA), influencing key biological processes including RNA stability, splicing, and translation. The dynamic modulation of m⁶A modification is mediated by an array of enzymes comprising methyltransferases (\"writers\"), demethylases (\"erasers\"), and m⁶A-binding proteins (\"readers\").As a pivotal member of the m⁶A \"writer\" family, RNA binding motif protein 15 (RBM15) facilitates the recruitment of the methyltransferase complex (MTC) to mRNA, thus orchestrating the addition of m⁶A modifications. Although prior research has underscored the critical role of m⁶A in oncogenesis, the precise mechanisms through which RBM15 operates in cancer are yet to be elucidated. This study endeavors to elucidate the structural characteristics and functional roles of RBM15, investigate its potential regulatory mechanisms across diverse tumors, uncover its distinct functions in tumor genesis, progression, and metastasis, and evaluate the therapeutic potential of targeting RBM15 in cancer treatment.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"855"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of lung adenocarcinoma subtype and prognosis model based on fatty acid metabolism-related genes.","authors":"Jing Chen, Jinyu Huang, Liangfang Shen","doi":"10.1007/s12672-025-02613-0","DOIUrl":"10.1007/s12672-025-02613-0","url":null,"abstract":"<p><strong>Objective: </strong>To explore the role of genes related to fatty acid metabolism in lung adenocarcinoma classification and prognosis.</p><p><strong>Methods: </strong>Transcriptome and clinical data from the TCGA database and GEO database were collected, the expression of prognostic fatty acid metabolism-related genes in LUAD patients was analyzed, and key genes related to both fatty acid metabolism and subtype were identified. These key genes were further filtered via the LASSO regression method, and the retained genes were used to construct a risk-scoring model. The biological function of RPS4Y1 was verified by cell viability, colony formation, migration, and flow cytometry assays. Finally, immune infiltration and drug sensitivity were analyzed in the high- and low-risk groups.</p><p><strong>Results: </strong>31 key FAMGs associated with prognosis were identified in LUAD patients. LUAD cases were divided into 3 subtypes on the basis of the expression of these genes. The DEGs between the different subtypes were associated mainly with amino acid metabolic pathways. In addition, among the 46 DEGs between subtypes, 5 key FAMGs (SCGB3 A2, PGC, ADH7, RPS4Y1, and KRT6 A) were identified as the best prognostic markers via LASSO regression to establish a risk scoring model. Patients with low risk scores had a better prognosis and a greater degree of immune cell infiltration than those with high risk scores. RPS4Y1 is highly expressed in LUAD, and its knockdown significantly inhibits the growth of tumor cells. Moreover, we also analyzed drugs likely to be effective for the high- and low-risk groups.</p><p><strong>Conclusion: </strong>FAMGs play important roles in LUAD, and the key genes identified may be new targets for LUAD treatment.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"866"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of a Novel Lactylation-related Gene Signature to Predict the Prognosis of Endometrial Cancer.","authors":"Linna Chen, Meng Xia, Weijia Wen, Li Yuan, Yan Jia, Xueyuan Zhao, Haolin Fan, Songlin Liu, Tianyu Liu, Pan Liu, Hongye Jiang, Wei Wang, Yuandong Liao, Chunyu Zhang, Shuzhong Yao","doi":"10.1007/s12672-025-02663-4","DOIUrl":"10.1007/s12672-025-02663-4","url":null,"abstract":"<p><strong>Background: </strong>Endometrial carcinoma (EC) is a prevalent kind of cancerous tumor with significant morbidity and mortality. Mounting evidence reveals that lactylation modification plays a crucial role in tumorigenesis, but its connection to EC remains poorly understood. This study aimed to identify a lactylation-related gene signature to predict the prognosis of EC.</p><p><strong>Methods: </strong>Differentially expressed lactylation-related genes between EC and normal samples were analyzed using the TCGA database. Univariate and LASSO Cox regression analyses were employed to construct the lactylation-related signature, which was then validated using both the test set and entire set. A nomogram was further developed and evaluated. Additionally, enrichment analysis, immune cell infiltration, tumor mutation burden and drug response were assessed between the two risk groups.</p><p><strong>Results: </strong>Sixteen lactylation-related genes (LRGs) were selected to construct the prognostic signature. Kaplan-Meier survival curves showed that patients in the high-risk group had remarkably worse prognosis. A nomogram based on the signature and other clinical characteristics was constructed and demonstrated strong predictive power. Additionally, biological pathways, immune status, tumor mutation burden and drug response differed between the high- and low-risk groups.</p><p><strong>Conclusion: </strong>In conclusion, our study demonstrated that the LRG signature is a promising biomarker for EC, effectively distinguishing high-risk patients, predicting prognosis, and offering new strategic directions for antitumor immunotherapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"862"},"PeriodicalIF":2.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}